[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 52 of about 52
1. Ahmed H, Cappello F, Rodolico V, Vasta GR: Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. Transl Oncol; 2009 Aug 18;2(3):146-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer.
  • Galectins, soluble intracellular and extracellular beta-galactoside-binding proteins, are known to be involved in the progression and metastasis of various cancers, including prostate adenocarcinoma, but the detailed mechanism of their biological roles remains elusive.
  • In the prostate cancer cell lines PC-3 and DU-145, galectin 3 (gal3) is present at normal levels, whereas in LNCaP, its expression is silenced.
  • On immunohistochemical analysis of normal and tumor prostate tissues, gal3 was found expressed both in nucleus and cytoplasm of benign prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia, and stage I.
  • On methylation analysis, the gal3 promoter in stage II prostate adenocarcinoma (PCa) was found heavily methylated, whereas in stages III and IV, it was only lightly methylated.
  • However, in stage I PCa, both heavy and light methylations were observed in the gal3 promoter.
  • The differential cytosine methylation in the gal3 promoter in stages I to IV PCa enabled us to develop and validate a methylation-specific polymerase chain reaction-based sensitive assay specific for stages I and II PCa.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):567-78 [17786537.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2353-63 [10590378.001]
  • [Cites] Scand J Immunol. 2007 Aug-Sep;66(2-3):143-58 [17635792.001]
  • [Cites] Cell Mol Life Sci. 2007 Jul;64(13):1679-700 [17497244.001]
  • [Cites] Front Biosci. 2007;12:3377-97 [17485307.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 22;358(1):241-6 [17481580.001]
  • [Cites] Urology. 2007 Apr;69(4):714-20 [17445657.001]
  • [Cites] Expert Opin Ther Targets. 2007 Jan;11(1):81-90 [17150036.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Sep;6(6):533-51 [17017872.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6569-75 [16170165.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8472-8 [15623627.001]
  • [Cites] Am J Clin Pathol. 1999 May;111(5):623-31 [10230352.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):519-26 [10225438.001]
  • [Cites] J Natl Cancer Inst. 1998 Jul 1;90(13):1000-8 [9665149.001]
  • [Cites] Arch Biochem Biophys. 1998 Jan 1;349(1):7-20 [9439577.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7252-7 [8692978.001]
  • [Cites] Curr Opin Genet Dev. 1995 Jun;5(3):309-14 [7549424.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):815-22 [7677193.001]
  • [Cites] J Urol. 1994 Jun;151(6):1571-4 [7514690.001]
  • [Cites] Int J Cancer. 1994 Feb 15;56(4):474-80 [8112883.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7527-36 [15326483.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5518-22 [15328191.001]
  • [Cites] Expert Rev Mol Diagn. 2004 Jul;4(4):513-26 [15225099.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4442-52 [15231653.001]
  • [Cites] J Mol Diagn. 2004 May;6(2):101-7 [15096565.001]
  • [Cites] Glycobiology. 2004 Mar;14(3):219-32 [14693912.001]
  • [Cites] Glycoconj J. 2004;19(7-9):537-42 [14758077.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] Cancer Treat Rev. 2002 Oct;28(5):255-71 [12435372.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5400-13 [12154403.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Cell Mol Life Sci. 2002 Feb;59(2):241-57 [11915942.001]
  • [Cites] Clin Chim Acta. 2001 Nov;313(1-2):143-6 [11694252.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2727-30 [11555585.001]
  • [Cites] Histol Histopathol. 2001 Jul;16(3):861-8 [11510978.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4820-6 [11406558.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5941-5 [11085508.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):361-7 [10956411.001]
  • [Cites] Clin Chem. 2000 Aug;46(8 Pt 1):1078-84 [10926886.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):118-23 [10881021.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6239-45 [10626818.001]
  • [Cites] Clin Chem. 2008 May;54(5):874-82 [18339699.001]
  • [Cites] Anticancer Agents Med Chem. 2008 Jan;8(1):22-36 [18220503.001]
  • [Cites] Urol Res. 1999 Oct;27(5):362-7 [10550525.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):605-10 [17726578.001]
  • (PMID = 19701499.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM070589
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2730137
  •  go-up   go-down


2. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R: Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res; 2008 Aug 15;68(16):6822-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
  • Herein, using transgenic adenocarcinoma of the mouse prostate (TRAMP) model, we assessed the "stage-specific" efficacy of silibinin feeding against prostate cancer (PCa) initiation, progression, angiogenesis and metastasis, and associated molecular events involved in silibinin effects during these stages.
  • Male TRAMP mice starting at ages 4, 12, 20, and 30 weeks of age were fed with control or 1% silibinin-supplemented diet for 8 to 15 weeks in stage-specific manners.
  • During early stages of prostate tumor development, silibinin mediated its efficacy mostly via antiproliferative mechanisms.
  • Feeding of silibinin to animals burdened with higher stages of prostate tumor significantly decreased tumor grade via antiproliferative effect, and inhibition of angiogenesis as evidenced by decreased expressions of platelet endothelial cell adhesion molecule-1/CD-31, vascular endothelial growth factor, and associated receptor, vascular endothelial growth factor R2, hypoxia-inducible factor-1alpha, and inducible nitric oxide synthase.
  • Together, these findings are both novel and highly significant in establishing the dual efficacy of silibinin where it inhibits progression of primary prostatic tumor and also shows protective efficacy against angiogenesis and late stage metastasis.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1404-13 [15831527.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15809-14 [9861052.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2104-15 [16208706.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2005 Nov;5(6):603-12 [16305482.001]
  • [Cites] Annu Rev Med. 2006;57:49-63 [16409136.001]
  • [Cites] Mol Carcinog. 2006 Jun;45(6):436-42 [16637061.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Aug;20(4):831-43 [16861117.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):751-78 [16954429.001]
  • [Cites] Oncogene. 2007 Mar 22;26(13):1862-74 [17043660.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(6):1082-8 [17416542.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5789-97 [17575146.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5976-82 [17575168.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Aug;7(5):475-83 [17691907.001]
  • [Cites] J Urol. 2007 Sep;178(3 Pt 2):S9-S13 [17644117.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):11083-91 [18006855.001]
  • [Cites] Food Chem Toxicol. 2008 Apr;46(4):1334-45 [17919802.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2736-43 [11289156.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6777-82 [11559550.001]
  • [Cites] Cancer Invest. 2002;20(1):139-53 [11852996.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):933-9 [14504208.001]
  • [Cites] Endocr Rev. 2003 Oct;24(5):600-32 [14570746.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(4):272-80 [14663466.001]
  • [Cites] Mol Endocrinol. 1994 Feb;8(2):230-9 [8170479.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Toxicol Pathol. 1996 Jul-Aug;24(4):502-4 [8864193.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4687-91 [9354422.001]
  • [Cites] J Cell Sci. 2005 Oct 1;118(Pt 19):4325-6 [16179603.001]
  • (PMID = 18701508.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112304-04; United States / NCI NIH HHS / CA / R01 CA112304; United States / NCI NIH HHS / CA / R01 CA112304-04; United States / NCI NIH HHS / CA / R01CA102514; United States / NCI NIH HHS / CA / R01 CA102514
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Silymarin; 0 / Vascular Endothelial Growth Factor A; 4RKY41TBTF / silybin; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  • [Other-IDs] NLM/ NIHMS55332; NLM/ PMC2587411
  •  go-up   go-down


3. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ: Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol; 2010 Mar 01;28(7):1106-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.
  • PURPOSE To test the hypothesis that increasing radiation dose delivered to men with early-stage prostate cancer improves clinical outcomes.
  • PATIENTS AND METHODS Men with T1b-T2b prostate cancer and prostate-specific antigen </= 15 ng/mL were randomly assigned to a total dose of either 70.2 Gray equivalents (GyE; conventional) or 79.2 GyE (high).
  • CONCLUSION This randomized controlled trial shows superior long-term cancer control for men with localized prostate cancer receiving high-dose versus conventional-dose radiation.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Conformal

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2002 Jan;167(1):123-6 [11743288.001]
  • [Cites] J Urol. 1991 Nov;146(5):1313-6 [1719244.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):81-9 [8988730.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1035-41 [9169810.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):299-304 [9788407.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):553-61 [10524405.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1233-9 [16160131.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74 [16798415.001]
  • [Cites] Lancet Oncol. 2007 Jun;8(6):475-87 [17482880.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74 [17765406.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):980-8 [18495377.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):3-12 [7721636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):436-41 [12243819.001]
  • [Cites] J Urol. 2004 Jan;171(1):210-4 [14665878.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):25-33 [14697417.001]
  • [Cites] J Urol. 2004 Apr;171(4):1393-401 [15017184.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] JAMA. 1979 May 4;241(18):1912-5 [107338.001]
  • [Cites] Biometrics. 1990 Mar;46(1):81-92 [2350572.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):935-9 [1917622.001]
  • [CommentIn] J Clin Oncol. 2010 Mar 1;28(7):1087-9 [20124163.001]
  • (PMID = 20124169.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA021239; United States / NCI NIH HHS / CA / P01 CA21239; United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA37422; United States / NCI NIH HHS / CA / U10 CA037422; United States / NCI NIH HHS / CA / U10 CA021661
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2834463
  •  go-up   go-down


Advertisement
4. Mhawech-Fauceglia P, Smiraglia DJ, Bshara W, Andrews C, Schwaller J, South S, Higgs D, Lele S, Herrmann F, Odunsi K: Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma. Cancer Epidemiol Biomarkers Prev; 2008 Mar;17(3):571-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma.
  • The aim of this study was to determine the role of prostate-specific membrane antigen (PSMA) as a prognostic marker in endometrial adenocarcinoma (EAC) and to explore whether its down-regulation could be due to epigenetic mechanism.
  • Higher PSMA mRNA levels were associated with stage I (P = 0.046) and PSMA protein intensity by immunohistochemistry (P = 0.032).
  • PSMA was methylated in prostate cell lines (DU145 and PC3) and endometrial cell lines.
  • In summary, (a) PSMA is underexpressed in advanced stage EAC, (b) loss of PSMA expression can be considered as a prognostic marker in patients with EAC, and (c) loss of PSMA expression in a subset of EAC cases could be due to epigenetic silencing.
  • [MeSH-major] Antigens, Surface / metabolism. Endometrial Neoplasms / metabolism. Glutamate Carboxypeptidase II / metabolism

  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349274.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Biomarkers, Tumor; EC 3.4.17.21 / Glutamate Carboxypeptidase II; EC 3.4.17.21 / glutamate carboxypeptidase II, human
  •  go-up   go-down


5. Lawton CA, DeSilvio M, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H: Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). Int J Radiat Oncol Biol Phys; 2007 Jan 1;67(1):39-47
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).
  • PURPOSE: To evaluate the effectiveness of transrectal ultrasound-guided permanent radioactive (125)I implantation of the prostate for organ-confined adenocarcinoma of the prostate compared with historical data of prostatectomy and external beam radiotherapy within a cooperative group setting.
  • METHODS AND MATERIALS: Patients accrued to this study had histologically confirmed, locally confined, adenocarcinoma of the prostate with clinical Stage T1b, T1c, or T2a, no nodal or metastatic disease, prostate-specific antigen level of < or =10 ng/mL, and Gleason score of < or =6.
  • All patients underwent transrectal ultrasound-guided radioactive (125)I permanent seed implantation into the prostate.
  • The prescribed dose was 145 Gy to the prostate planning target volume.
  • At last follow-up, no patient had died of prostate cancer or related toxicities.
  • CONCLUSION: The results of this clinical protocol (a multi-institutional trial of brachytherapy for localized adenocarcinoma of the prostate) have demonstrated that this type of trial can be successfully completed through the Radiation Therapy Oncology Group.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Prostatic Neoplasms / radiotherapy. Ultrasonography, Interventional / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Disease-Free Survival. Humans. Iodine Radioisotopes / therapeutic use. Male. Middle Aged. Neoplasm Staging. Prognosis. Prostate-Specific Antigen / blood. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084551.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


6. Kannan V, Sathiyanarayanan VK, Sagde S, Anand V, Almel S, Kapadia A, Srinivas V: Three dimensional conformal radiation therapy in prostate adenocarcinoma: survival and rectal toxicity. J Cancer Res Ther; 2005 Jan-Mar;1(1):34-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three dimensional conformal radiation therapy in prostate adenocarcinoma: survival and rectal toxicity.
  • The 3D-CRT clinical treatment in our hospital was started in September 1998 and till December 2002, 51 patients with M(0) stage prostate carcinoma were treated.
  • The acute rectal reaction (RTOG criteria) in 51 patients was grade 0 in 4, grade I in 31 and grade II in 16.
  • None had greater than grade II rectal toxicity.
  • The late rectal toxicity in 49 patients who had a minimum 6 months follow-up was grade 0 in 41, grade I in 3 and grade II in 5.
  • Our experience suggests that a dose of 72 Gy by 3D-CRT can be safely delivered to the prostate and gastrointestinal tolerance during treatment and follow-up period was excellent.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Rectum / radiation effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998623.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


7. Zhu AX, Wallner KE, Frivold GP, Ferry D, Jutzy KR, Foster GP: Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction. Brachytherapy; 2006 Oct-Dec;5(4):262-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction.
  • PURPOSE: We report a case of prostate brachytherapy seed migration to the right coronary artery (RCA) associated with an acute myocardial infarction (AMI).
  • METHODS AND MATERIALS: A 69-year-old male was diagnosed with Prostate Adenocarcinoma Stage II (T(1c)N0M0) in October 2003.
  • He underwent percutaneous transperineal interstitial permanent prostate brachytherapy with the implantation of 94 loose iodine (125I) seeds under transrectal ultrasound guidance on 15 December, 2003.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / adverse effects. Coronary Vessels. Myocardial Infarction / etiology. Prostatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17118321.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


8. Liang JJ, Zhu S, Bruggeman R, Zaino RJ, Evans DB, Fleming JB, Gomez HF, Zander DS, Wang H: High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev; 2010 Oct;19(10):2598-604
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
  • BACKGROUND: Stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4, have been shown to mediate invasiveness and metastatic behavior in a number of cancers, including ovarian, prostate, bladder, breast, and pancreatic cancers.
  • The expression and significance of SDF-1 in pancreatic ductal adenocarcinoma (PDA) have not been systematically studied.
  • METHODS: We examined the expression of SDF-1 by immunohistochemistry using a mouse anti-human SDF-1/CXCL12 antibody (dilution 1:300) and a tissue microarray consisting of 72 stage II PDAs from pancreaticoduodenectomy specimens.
  • RESULT: Of the 72 stage II PDAs, 25 (35%) showed high levels of SDF-1 expression.
  • CONCLUSION: High levels of SDF-1 expression were associated with poor overall and disease-free survival in patients with stage II PDA.
  • SDF-1 may serve as a useful prognostic marker for stage II PDA.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Pancreatic Ductal / metabolism. Chemokine CXCL12 / biosynthesis. Pancreatic Neoplasms / metabolism

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 20732965.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chemokine CXCL12
  •  go-up   go-down


9. Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, Gospodarowicz M, McLean M, Ménard C, Milosevic M, Warde P, Catton C: Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys; 2007 Nov 15;69(4):1084-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma.
  • PURPOSE: To assess in a prospective trial the feasibility and late toxicity of hypofractionated radiotherapy (RT) for prostate cancer.
  • METHODS AND MATERIALS: Eligible patients had clinical stage T1c-2cNXM0 disease.
  • The cohort had a median prostate-specific antigen value of 7.06 ng/mL.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Aged. Biopsy. Dose Fractionation. Feasibility Studies. Humans. Male. Prospective Studies. Prostate / pathology. Prostate-Specific Antigen / blood. Salvage Therapy / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606331.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


10. Mumenthaler SM, Rozengurt N, Livesay JC, Sabaghian A, Cederbaum SD, Grody WW: Disruption of arginase II alters prostate tumor formation in TRAMP mice. Prostate; 2008 Oct 1;68(14):1561-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disruption of arginase II alters prostate tumor formation in TRAMP mice.
  • BACKGROUND: Arginase II (AII) is involved in the polyamine synthetic pathway, and elevated levels of expression have been found in a high proportion of prostate cancer samples and patients.
  • However, the biological function of arginase II in prostate cancer still remains to be elucidated.
  • In this study, we utilized the TRAMP mouse prostate cancer model to better understand the contribution of AII on tumor development.
  • Additionally, AII expression was disrupted in the TRAMP model by crossbreeding arginase II knockout (AII KO) mice with TRAMP mice in order to generate the TRAMP/AII KO line.
  • RESULTS: AII expression was only detectable in those mice without the presence of macroscopic tumors; it was also absent in the TRAMP-C2 cell line, which is characteristic of an advanced prostate tumor.
  • CONCLUSIONS: Based on these results, AII deficiency in the TRAMP model seems to accelerate prostate tumor progression, leading to an overall more advanced cancer stage in these mice.
  • These findings support the possibility that prostatic arginase II could be a potentially useful marker of disease progression.
  • [MeSH-major] Adenocarcinoma / enzymology. Arginase / metabolism. Prostatic Neoplasms / enzymology. Receptors, Tumor Necrosis Factor, Member 25 / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663728.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16042; United States / NCI NIH HHS / CA / CA92131
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm; 0 / Receptors, Tumor Necrosis Factor, Member 25; 0 / Tnfrsf25 protein, mouse; EC 3.5.3.1 / Arg2 protein, mouse; EC 3.5.3.1 / Arginase
  •  go-up   go-down


11. Sonpavde G, Frolov A, Macdonell V, Hayes TG, Mims MP, Ayala GE, Wheeler TM, Thompson TC, Ittman MM, Kadmon D: Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP). J Clin Oncol; 2009 May 20;27(15_suppl):5127

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP).
  • METHODS: A phase II trial was designed to evaluate bortezomib 1.6mg/m<sup>2</sup> as intravenous bolus weekly for 4 weeks followed by RP 24-72 hours after the last dose.
  • Histological evidence of adenocarcinoma of the prostate was required with clinical stage T<sub>1c</sub> or T<sub>2a</sub> with Gleason 8-10 disease, or clinical stage T<sub>2b</sub>-T<sub>2c</sub> with Gleason grade 7 and PSA of >10 ng/mL, or clinical stage T<sub>3</sub>.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Bălăşoiu M, Turculeanu A, Avrămescu C, Comănescu V, Simionescu C, Mogoantă L: Cytokines levels in prostate adenocarcinomas. Rom J Morphol Embryol; 2005;46(3):179-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokines levels in prostate adenocarcinomas.
  • In this research, we determined the levels of IL-2, IL-6 and TNF-alpha at 60 patients with prostate adenocarcinomas situated in II, III and IV stages.
  • We observed that the IL-2 levels were normal in II stage, and the levels of IL-6 and TNF-alpha were lightly increased.
  • In III and IV stages of prostate cancer the levels of IL-2 were very low and the levels of IL-6 and TNF-alpha were very increased.
  • The decrease of IL-2 levels in advanced prostate cancer goes to the decrease of immune response in prostate cancer.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / pathology. Cytokines / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444302.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-2; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


13. Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE, Seligson DB, Grody WW: Expression of arginase II in prostate cancer. Int J Oncol; 2008 Feb;32(2):357-65
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of arginase II in prostate cancer.
  • Previous reports have shown elevated arginase activity in prostate cancer patients.
  • This study was designed to compare expression levels of arginase II (AII) in various human prostate cancer cell lines and tissues.
  • Expression levels of AII and other enzymes involved in arginine metabolism were examined in androgen-dependent (LNCaP, LAPC-4) and androgen-independent (PC3, DU145, CL-1, CL-2) prostate cancer cell lines by real-time RT-PCR and Western blot analysis.
  • In addition, polyamine levels were measured within the prostate cancer cell lines by HPLC.
  • The tissue microarray data revealed that the highest AII expression was seen in BPH, followed by PIN and normal samples, with the lowest expression levels observed in prostate cancer tissues.
  • Based on these results, arginase II expression may play a role in prostate cancer progression.
  • More specifically, the elevated AII expression seen in androgen-dependent and in more differentiated prostate cancers suggests that AII could be a potentially useful marker of early stage prostate adenocarcinoma.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18202758.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16042; United States / NCI NIH HHS / CA / CA 92131
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Androgens; 0 / Biomarkers, Tumor; 0 / Polyamines; 0 / Receptors, Androgen; 94ZLA3W45F / Arginine; EC 2.6.1.13 / Ornithine-Oxo-Acid Transaminase; EC 3.5.3.1 / Arginase; EC 3.5.3.1 / arginase II, human
  •  go-up   go-down


14. Hsu IC, Bae K, Shinohara K, Pouliot J, Purdy J, Ibbott G, Speight J, Vigneault E, Ivker R, Sandler H: Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys; 2010 Nov 1;78(3):751-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321.
  • PURPOSE: To estimate the rate of late Grade 3 or greater genitourinary (GU) and gastrointestinal (GI) adverse events (AEs) after treatment with external beam radiotherapy and prostate high-dose-rate (HDR) brachytherapy.
  • Patients with locally confined Stage T1c-T3b prostate cancer were eligible for the present study.
  • The pretreatment characteristics of the patients were as follows: Stage T1c-T2c, 91%; Stage T3a-T3b, 9%; prostate-specific antigen level ≤10 ng/mL, 70%; prostate-specific antigen level >10 but ≤20 ng/mL, 30%; and Gleason score 2-6, 10%; Gleason score 7, 72%; and Gleason score 8-10, 18%.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):851-8 [10705005.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):814-9 [18407435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):343-52 [10802358.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):61-9 [11163498.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1021-31 [11429230.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):81-90 [11777625.001]
  • [Cites] J Urol. 2003 Mar;169(3):974-9; discussion 979-80 [12576825.001]
  • [Cites] Radiother Oncol. 2003 Sep;68(3):285-8 [13129636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1063-71 [15001246.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1019-27 [7493828.001]
  • [Cites] Radiother Oncol. 1997 Sep;44(3):237-44 [9380822.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):525-33 [9635698.001]
  • [Cites] Radiother Oncol. 1998 Aug;48(2):197-202 [9783892.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1095-101 [10192361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):747-8 [10386630.001]
  • [Cites] Strahlenther Onkol. 1999 Jun;175 Suppl 2:87-8 [10394408.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):804-9 [16289906.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2006;9(3):245-53 [16786040.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):416-23 [16879929.001]
  • [Cites] Cancer. 2007 Apr 15;109(8):1506-12 [17340591.001]
  • [Cites] Radiother Oncol. 2007 Aug;84(2):114-20 [17531335.001]
  • [Cites] J Appl Clin Med Phys. 2007;8(4):2415 [18449148.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1205-11 [10725633.001]
  • (PMID = 20207506.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / U24 CA081647; United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10CA37422; United States / NCI NIH HHS / CA / U24 CA81647; United States / NCI NIH HHS / CA / U10 CA037422; United States / NCI NIH HHS / CA / U10 CA021661; United States / NCI NIH HHS / CA / U10 CA032115
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS209285; NLM/ PMC2946454
  •  go-up   go-down


15. Nihei K, Ogino T, Ishikura S, Kawashima M, Nishimura H, Arahira S, Onozawa M: Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan. Jpn J Clin Oncol; 2005 Dec;35(12):745-52
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan.
  • OBJECTIVE: To assess the feasibility of high-dose radiotherapy for prostate cancer using proton boost therapy following photon radiotherapy.
  • The study included patients with clinical stage T1-3N0M0 prostate cancer.
  • Radiotherapy consisted of 50 Gy/25 fx photon irradiation to the prostate and the bilateral seminal vesicles followed by proton boost of 26 Gy(E)/13 fx to the prostate alone.
  • CONCLUSIONS: Proton boost therapy following photon radiotherapy for prostate cancer is feasible.
  • To evaluate the efficacy and safety of proton beam therapy, a multi-institutional phase II trial is in progress in Japan.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Conformal / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314345.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Yee DS, Narula N, Ramzy I, Boker J, Ahlering TE, Skarecky DW, Ornstein DK: Reduced annexin II protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Arch Pathol Lab Med; 2007 Jun;131(6):902-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced annexin II protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer.
  • CONTEXT: Annexin II is a calcium-dependent phospholipid-binding protein that plays a role in many cellular functions, including apoptosis, signal transduction, and cellular motility.
  • Although commonly underexpressed in prostate cancer, the association of reduced expression with pathologic grade and stage is unknown.
  • OBJECTIVE: To compare annexin II expression in benign prostatic lesions with expression in high-grade prostatic intraepithelial neoplasia and prostate cancer, as well as to correlate expression levels with pathologic grade and stage.
  • DESIGN: A semi-quantitative assessment of annexin II expression was performed in radical prostatectomy specimens from 74 patients and prostate needle core biopsy specimens from 13 patients.
  • Foci with normal prostatic glands, atrophic glands, basal cell hyperplasia, high-grade prostatic intraepithelial neoplasia, and prostatic adenocarcinoma were evaluated.
  • RESULTS: Annexin II expression was present in more than 50% of glands in most (>85%) samples of benign prostatic epithelium, atrophic glands, and basal cell hyperplasia.
  • In high-grade prostatic intraepithelial neoplasia, annexin II staining was markedly reduced in epithelial cells but not in basal cells.
  • Annexin II was absent or focally present in moderately differentiated adenocarcinoma but was retained in poorly differentiated adenocarcinomas.
  • CONCLUSIONS: Reduced annexin II expression may be a useful diagnostic biomarker to help identify small foci of moderately differentiated adenocarcinoma on needle core biopsy specimens since it is consistently expressed in benign prostatic glands.
  • Re-expression of annexin II in poorly differentiated adenocarcinoma may provide prognostic information.
  • [MeSH-major] Adenocarcinoma / metabolism. Annexin A2 / metabolism. Prostate / metabolism. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Neoplasms / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550317.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A2; 0 / Biomarkers, Tumor
  •  go-up   go-down


17. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G: Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol; 2009 Sep 1;27(25):4047-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.
  • PURPOSE: Prostatic acid phosphatase (PAP) is a prostate tumor antigen.
  • We report here the results of a phase I/IIa trial conducted with a DNA vaccine encoding human PAP in patients with stage D0 prostate cancer.
  • Overall, the prostate-specific antigen (PSA) doubling time was observed to increase from a median 6.5 months pretreatment to 8.5 months on-treatment (P = .033), and 9.3 months in the 1-year post-treatment period (P = .054).
  • CONCLUSION: The demonstration that a DNA vaccine encoding PAP is safe, elicits an antigen-specific T-cell response, and may be associated with an increased PSA doubling time suggests that a multi-institutional phase II trial designed to evaluate clinical efficacy is warranted.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3461-7 [10550143.001]
  • [Cites] Immunol Invest. 2000 May;29(2):149-62 [10854184.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Prostate. 2001 May 15;47(3):222-9 [11351352.001]
  • [Cites] J Surg Res. 2002 Feb;102(2):137-43 [11796010.001]
  • [Cites] J Immunol Methods. 2003 Jul;278(1-2):79-93 [12957398.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5):659-66 [14571413.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):688-94 [15280930.001]
  • [Cites] Anat Rec. 1985 Oct;213(2):131-9 [3907418.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 16;89(14):1049-58 [9230887.001]
  • [Cites] J Immunol. 1997 Oct 1;159(7):3113-7 [9317107.001]
  • [Cites] JAMA. 1999 May 5;281(17):1591-7 [10235151.001]
  • [Cites] JAMA. 2005 Jul 27;294(4):433-9 [16046649.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):456-62 [15927415.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8669-73 [16361552.001]
  • [Cites] Vaccine. 2006 Jan 16;24(3):293-303 [16115700.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3089-94 [16809734.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jun;56(6):885-95 [17102977.001]
  • [Cites] Curr Opin Urol. 2007 May;17(3):175-81 [17414515.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1765-71 [17470867.001]
  • [Cites] Clin Adv Hematol Oncol. 2007 Jun;5(6):465-74, 477-9 [17679921.001]
  • [CommentIn] J Clin Oncol. 2010 Feb 1;28(4):e58; author reply e59 [20008614.001]
  • [CommentIn] J Clin Oncol. 2009 Sep 1;27(25):4035-7 [19635998.001]
  • (PMID = 19636017.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR016489; United States / NCRR NIH HHS / RR / UL1 RR025011; United States / NCRR NIH HHS / RR / 1UL1RR025011; United States / NCRR NIH HHS / RR / K23 RR16489
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Cancer Vaccines; 0 / Recombinant Proteins; 0 / Vaccines, DNA; 123774-72-1 / sargramostim; 82115-62-6 / Interferon-gamma; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC2734418
  •  go-up   go-down


18. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G: Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res; 2009 Jun;15(2):167-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis.
  • Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in advanced stage prostate adenocarcinomas.
  • Paraffin-embedded sections of 51 patients with primary prostate carcinoma and distant metastases were evaluated.
  • Our findings clearly support the feasibility but also direct to potential failures of PSMA-targeted in vivo diagnostic and therapeutic approaches in prostate cancer patients with distant metastasis.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Surface / metabolism. Cell Membrane / metabolism. Cytoplasm / metabolism. Glutamate Carboxypeptidase II / metabolism. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18802790.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Surface; EC 3.4.17.21 / Glutamate Carboxypeptidase II; EC 3.4.17.21 / glutamate carboxypeptidase II, human
  •  go-up   go-down


19. Colonias A, Farinash L, Miller L, Jones S, Medich DS, Greenberg L, Miller R, Parda DS: Multidisciplinary treatment of synchronous primary rectal and prostate cancers. Nat Clin Pract Oncol; 2005 May;2(5):271-4; quiz 1 p following 274
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary treatment of synchronous primary rectal and prostate cancers.
  • Laboratory tests showed an elevated serum prostate-specific antigen of 32 ng/ml but other physical and medical examinations were unremarkable.
  • INVESTIGATIONS: Digital rectal examination, colonoscopy, rectal mass biopsy, endorectal ultrasound, transrectal ultrasound-guided prostate biopsy, CT scan and MRI.
  • DIAGNOSIS: Clinical stage III (T3N1M0), moderately differentiated adenocarcinoma of the rectum and clinical stage II (T1cN0M0) adenocarcinoma of the prostate.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasms, Multiple Primary / pathology. Prostatic Neoplasms / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16264963.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


20. Pu H, Collazo J, Jones E, Gayheart D, Sakamoto S, Vogt A, Mitchell B, Kyprianou N: Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model. Cancer Res; 2009 Sep 15;69(18):7366-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
  • The contribution of a dysfunctional transforming growth factor-beta type II receptor (TGF beta RII) to prostate cancer initiation and progression was investigated in an in vivo mouse model.
  • Transgenic mice harboring the dominant-negative mutant TGF-beta type II receptor (DNTGF beta RII) in mouse epithelial cell were crossed with the TRAMP prostate cancer transgenic mouse to characterize the in vivo consequences of inactivated TGF-beta signaling on prostate tumor initiation and progression.
  • Histopathologic diagnosis of prostate specimens from the TRAMP+/DNTGF beta RII double transgenic mice revealed the appearance of early malignant changes and subsequently highly aggressive prostate tumors at a younger age, compared with littermates TRAMP+/Wt TGF beta RII mice.
  • A significant increase in the androgen receptor mRNA and protein levels was associated with the early onset of prostate tumorigenesis in TRAMP+/DNTGF beta RII mice.
  • Our results indicate that in vivo disruption of TGF-beta signaling accelerates the pathologic malignant changes in the prostate by altering the kinetics of prostate growth and inducing EMT.
  • The study also suggests that a dysfunctional TGF beta RII augments androgen receptor expression and promotes inflammation in early stage tumor growth, thus conferring a significant contribution by TGF-beta to prostate cancer progression.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Biochem J. 2008 Dec 15;416(3):453-62 [18651839.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1996 Oct;1(4):365-72 [10887510.001]
  • [Cites] Cell. 2000 Oct 13;103(2):295-309 [11057902.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2112-8 [11280774.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3550-5 [11325816.001]
  • [Cites] Cell. 2001 May 18;105(4):425-31 [11371340.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S44-51 [11684442.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):1240-8 [11707452.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):34-45 [11900250.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2679-94 [11965541.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):43749-56 [12226080.001]
  • [Cites] Toxicol Pathol. 2003 Jan-Feb;31(1):31-8 [12597447.001]
  • [Cites] Curr Drug Targets. 2003 Apr;4(3):197-207 [12643470.001]
  • [Cites] Cell. 2003 Jun 13;113(6):685-700 [12809600.001]
  • [Cites] Neoplasia. 2003 May-Jun;5(3):267-77 [12869309.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Dig Dis Sci. 2003 Oct;48(10):1990-7 [14627346.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):47853-61 [14500729.001]
  • [Cites] Nat Med. 2004 Jan;10(1):33-9 [14702632.001]
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):483-90 [14755679.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):440-8 [14760063.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):491-8 [14760070.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):290-7 [15017584.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1488-90 [15470210.001]
  • [Cites] Mol Cell Biol. 1993 Sep;13(9):5266-75 [8355681.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Int J Cancer. 1997 May 16;71(4):573-9 [9178810.001]
  • [Cites] EMBO J. 1997 May 15;16(10):2621-33 [9184209.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4687-91 [9354422.001]
  • [Cites] Cell Growth Differ. 1998 Feb;9(2):185-93 [9486855.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1366-71 [10096572.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4834-42 [10519393.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9209-16 [15604294.001]
  • [Cites] Breast Cancer Res. 2005;7(1):33-6 [15642180.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2296-302 [15781643.001]
  • [Cites] J Urol. 2005 May;173(5):1562-6 [15821486.001]
  • [Cites] JAMA. 2005 May 4;293(17):2095-101 [15870412.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3302-3 [15738529.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):1051-8 [16257107.001]
  • [Cites] Urol Oncol. 2005 Nov-Dec;23(6):402-6 [16301117.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):464-72 [16397262.001]
  • [Cites] Prostate. 2006 May 1;66(6):632-50 [16388503.001]
  • [Cites] J Cell Biochem. 2006 May 1;98(1):36-53 [16440300.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5159-64 [16707439.001]
  • [Cites] Nature. 2006 May 25;441(7092):444-50 [16724056.001]
  • [Cites] J Cell Biochem. 2006 Oct 1;99(2):333-44 [16518832.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11238-46 [17114237.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5262-70 [17875754.001]
  • [Cites] Prostate. 2008 Feb 15;68(3):287-95 [18163430.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Leukoc Biol. 2008 May;83(5):1136-44 [18285406.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12182-7 [18723679.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8173-82 [18829577.001]
  • [Cites] Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):159-68 [10708963.001]
  • (PMID = 19738062.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK053525-07; United States / NIEHS NIH HHS / ES / T32 ES007266; United States / NIDDK NIH HHS / DK / R01 DK053525; United States / NIDDK NIH HHS / DK / R01 DK053525-07; United States / NIDDK NIH HHS / DK / R01 DK5355-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Androgen; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  • [Other-IDs] NLM/ NIHMS135291; NLM/ PMC2747670
  •  go-up   go-down


21. Lara PN Jr, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR: A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs; 2009 Mar;20(3):179-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
  • Prostate cancer cells undergo neuroendocrine differentiation during androgen deprivation and secrete neuropeptides, hence activating androgen receptor-regulated genes.
  • Src-family protein kinases are involved in neuropeptide-induced prostate cancer growth and migration.
  • A phase II trial of AZD0530, an oral Src-family kinase inhibitor, in patients with advanced castration resistant prostate cancer was conducted.
  • The primary endpoint was prostate cancer-specific antigen (PSA) response rate, defined as a 30% or greater decrease.
  • A two-stage Simon design was used.
  • Rapid accrual led to 28 patients registering in the first stage.
  • Strong preclinical evidence warrants further investigation of AZD0530 in earlier-stage prostate cancer or as combination therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Benzodioxoles / therapeutic use. Prostatic Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. src-Family Kinases / antagonists & inhibitors
  • [MeSH-minor] Aged. Aged, 80 and over. Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Chemical and Drug Induced Liver Injury / etiology. Combined Modality Therapy. Disease-Free Survival. Drug Resistance, Neoplasm. Gastrointestinal Diseases / chemically induced. Humans. Lymphopenia / chemically induced. Male. Middle Aged. Orchiectomy. Prostate-Specific Antigen / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3461-7 [10550143.001]
  • [Cites] Oncogene. 2008 Oct 23;27(49):6365-75 [18679417.001]
  • [Cites] Urology. 2000 Mar;55(3):323-7 [10699601.001]
  • [Cites] Oncogene. 2001 Mar 8;20(10):1152-63 [11313859.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(24):8385-97 [11713275.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):344-51 [11900220.001]
  • [Cites] J Bone Joint Surg Am. 2003 Aug;85-A(8):1544-52 [12925636.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2197-205 [14767470.001]
  • [Cites] Exp Cell Res. 1984 Jul;153(1):245-8 [6547391.001]
  • [Cites] Prostate. 1988;12(1):39-46 [2450341.001]
  • [Cites] Regul Pept. 1989 Apr;25(1):1-9 [2655036.001]
  • [Cites] Biochem Pharmacol. 1990 Mar 15;39(6):985-90 [2157441.001]
  • [Cites] J Urol. 1991 Aug;146(2):358-61 [1856931.001]
  • [Cites] Urology. 1994 May;43(5):675-9 [8165768.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5330-4 [8202489.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1240-6 [7977947.001]
  • [Cites] Nature. 1998 May 7;393(6680):83-5 [9590694.001]
  • [Cites] Prostate Suppl. 1998;8:52-61 [9690664.001]
  • [Cites] Oncogene. 2005 Apr 28;24(19):3110-20 [15735682.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9185-9 [16230377.001]
  • [Cites] Mol Cancer Ther. 2006 Mar;5(3):621-9 [16546976.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 19;98(8):516-21 [16622120.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10449-59 [17079466.001]
  • [Cites] Neoplasia. 2007 Feb;9(2):90-100 [17357254.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2250-8 [18381431.001]
  • [Cites] Anticancer Agents Med Chem. 2008 Apr;8(3):342-9 [18393792.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2506-13 [10561316.001]
  • (PMID = 19396016.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01 CM062209; United States / NCI NIH HHS / CA / N01CM62209; United States / NCI NIH HHS / CM / N01-CM62209; United States / NCI NIH HHS / CM / N0I-CM17102
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Benzodioxoles; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 9KD24QGH76 / saracatinib; EC 2.7.10.2 / src-Family Kinases; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS330482; NLM/ PMC3225398
  •  go-up   go-down


22. Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, Wang L, Tran-Thanh D, Pham NA, Tsao MS, Hedley D, Dancey JE, Moore MJ: A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol; 2010 Dec;33(6):609-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
  • Since EGFR and HER2 overexpression has also been seen in prostate cancer and appears to correlate with a worse clinical outcome, Lapatinib may represent a novel therapeutic strategy in prostate cancer.
  • This Phase II multicenter clinical trial is the first to evaluate Lapatinib in early stage, hormonally untreated recurrent or metastatic prostate cancer.
  • The primary end point was prostate specific antigen (PSA) response.
  • CONCLUSIONS: Lapatinib was well tolerated but like other EGFR- and HER2-targeted agents in advanced HRPC failed to show significant antitumor activity even in this very early stage hormonally untreated population.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Neoplasm Recurrence, Local / pathology. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Quinazolines / therapeutic use
  • [MeSH-minor] Administration, Oral. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prostate-Specific Antigen / blood. Risk Assessment. Single-Blind Method. Survival Rate. Treatment Outcome


23. Stathopoulos GP, Koutantos J, Vaslamatzis MM, Athanasiadis A, Papadopoulos G, Labrodimou G, Stathopoulos J, Rigatos S: Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study. Oncol Rep; 2009 Aug;22(2):345-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.
  • In the past, it was believed that when advanced-stage prostate cancer became resistant to hormonal management, no chemotherapy should be administered, as survival was not prolonged.
  • The objective of the present phase II study was to determine the survival and the response rate of patients after the chemotherapy was administered.
  • Sixty-five patients with advanced prostate cancer were included.
  • The inclusion criteria involved histological confirmation of adenocarcinoma and resistance to hormonal therapy.
  • The majority of the patients had stage IVa or IVb disease and a performance status of 0-1 to 2.
  • The hormone treatment preceded the cytotoxic administration and no amelioration in the patients nor prostate serum antigen (PSA) reduction was observed.
  • Patients with hormone-resistant advanced prostate cancer do have good prospects for receiving substantial benefit with the addition of chemotherapy, as observed in the present trial.


24. Shepard DR, Dreicer R, Garcia J, Elson P, Magi-Galluzzi C, Raghavan D, Stephenson AJ, Klein EA: Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. J Urol; 2009 Apr;181(4):1672-7; discussion 1677
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
  • PURPOSE: Taxane based chemotherapy has activity in advanced prostate cancer but previous studies of neoadjuvant docetaxel demonstrated a prostate specific antigen response with no obvious antitumor activity.
  • The efficacy and safety of neoadjuvant albumin-bound paclitaxel (nab-paclitaxel, Abraxane), a novel nanoparticle based formulation, were assessed in patients with high risk, locally advanced prostate cancer.
  • MATERIALS AND METHODS: Eligible patients had locally advanced prostatic adenocarcinoma, clinical stage cT2b or greater, Gleason score 8 or greater, or serum prostate specific antigen 15 ng/ml or greater without metastatic disease.
  • Efficacy assessments included pathological and prostate specific antigen response.
  • Median pretreatment prostate specific antigen was 8.5 ng/ml and median Gleason score was 8.
  • Post-chemotherapy prostate specific antigen was decreased in 18 of 19 (95%) patients and median decrease was 2.9 ng/ml (35%, p <0.001).
  • An initial prostate specific antigen after radical prostatectomy of 0.02 ng/ml or less was achieved in 17 of 18 (94%) patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Albumins / therapeutic use. Paclitaxel / therapeutic use. Prostatectomy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19230915.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 130-nm albumin-bound paclitaxel; 0 / Albumins; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


25. Suy S, Oermann E, Hanscom H, Lei S, Vahdat S, Yu X, Park HU, Chen V, Collins BT, McGeagh K, Dawson N, Jha R, Azumi N, Dritschilo A, Lynch J, Collins SP: Histopathologic effects of hypofractionated robotic radiation therapy on malignant and benign prostate tissue. Technol Cancer Res Treat; 2010 Dec;9(6):583-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic effects of hypofractionated robotic radiation therapy on malignant and benign prostate tissue.
  • A 66 year-old man presented with stage II, low risk adenocarcinoma of the prostate and underwent elective conformal hypofractionated radiation therapy.
  • His pretreatment evaluation revealed T1c adenocarcinoma, Gleason's grade 3 + 3 = 6 and a prostate specific antigen (PSA) level of 4.87 ng/ml.
  • Histolopathologic analyses of resected prostate tissues revealed changes consistent with radiation treatment, including cellular changes, inflammation, glandular atrophy and hyperplasia.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Dose Fractionation. Prostate / pathology. Prostate / radiation effects. Prostatic Neoplasms / radiotherapy. Radiotherapy, Conformal / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21070080.001).
  • [ISSN] 1533-0338
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Tsuji H, Yanagi T, Ishikawa H, Kamada T, Mizoe JE, Kanai T, Morita S, Tsujii H, Working Group for Genitourinary Tumors: Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys; 2005 Nov 15;63(4):1153-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated radiotherapy with carbon ion beams for prostate cancer.
  • PURPOSE: Analysis of the results of hypofractionated conformal carbon ion radiotherapy for localized prostate cancer was performed, with special regard to normal tissue morbidity and biochemical relapse-free rate (bNED).
  • Gleason score, initial PSA, and T stage were all significant prognostic factors for bNED, which was 97.1% in patients with Gleason score < or =7 and initial PSA <20 ng/mL.
  • Long-term results are necessary to confirm the utility of carbon ion radiotherapy in the treatment of localized prostate cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carbon Radioisotopes / therapeutic use. Prostatic Neoplasms / radiotherapy. Radiotherapy, Conformal / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990247.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes
  •  go-up   go-down


27. Stojanovic S, Radosvic-Jelic Lj, Tulic C, Popov I, Babic D, Acimovic M, Masulovic D: Radical radiotherapy for localized prostate cancer in elderly. Acta Chir Iugosl; 2005;52(4):103-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical radiotherapy for localized prostate cancer in elderly.
  • BACKGROUND: Prostate cancer is an age related neoplasm, with high incidence in the group of elderly man.
  • AIM: The aim of this study was to determine the role of radical radiotherapy for localized prostate carcinoma in patients 70 years age or older concerning treatment morbidity, local control, disease free and overall survival.
  • Stage distribution was as follows: stage A--3 patients (2.9%), stage B--69 patients (67%) and stage C--31 patients (30.1%).
  • Late sequelas (gradus I and II) are registered in 22 patients (21.36%), out of 103.
  • CONCLUSION: Radical radiotherapy for localized carcinoma of the prostate is effective treatment option in elderly patients with good local control, present treatment tolerance providing good quality of life and long-term cure.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Humans. Male. Prostate-Specific Antigen / blood. Radiation Injuries. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16673605.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Serbia and Montenegro
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


28. Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM: A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anticancer Drugs; 2010 Apr;21(4):433-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
  • Taxanes remain the only agents to extend survival in castration-resistant metastatic prostate cancer, but their impact on the natural history of this disease is modest.
  • Patients with metastatic adenocarcinoma of the prostate who progressed despite standard hormonal therapy and after docetaxel-containing chemotherapy were treated with transdermal estradiol (0.2 mg/24 h) for 4 weeks followed by the same dose of transdermal estradiol and paclitaxel poliglumex (PPX; 150 mg/m intravenous) every 28 days.
  • The primary objective was to determine the level of activity of the regimen measured using a fraction of patients who experienced a confirmed decline in serum prostate-specific antigen (PSA) of 50% or more.
  • A two-stage phase II study designed to identify a response rate of > or =25% required three responders among 21 patients in the first stage.
  • In conclusion, this regimen of low-dose transdermal estradiol induction followed by PPX does not have activity in taxane pretreated patients with castration-resistant prostate cancer.


29. Ishikawa H, Tsuji H, Kamada T, Yanagi T, Mizoe JE, Kanai T, Morita S, Wakatsuki M, Shimazaki J, Tsujii H, Working Group for Genitourinary Tumors: Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol; 2006 Oct;81(1):57-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study.
  • BACKGROUND AND PURPOSE: To determine the efficacy and feasibility of carbon ion radiotherapy (C-ion RT) for prostate cancer.
  • C-ion RT alone was performed for 33 patients constituting a low-risk group (Stage < or =T2a and PSA <20 ng/ml and Gleason score < or =6); the remaining 142 high-risk patients received an additional androgen deprivation therapy (ADT).
  • In very advanced diseases (Stage > or= T3a or PSA > or= 20 ng/ml or Gleason score > or =8), there was significant difference in the bNED rate according to period of ADT administration (ADT > or =24 months: 93%, ADT <24 months: 73%, p<0.01).
  • CONCLUSIONS: The effectiveness of C-ion RT for prostate cancer has been well confirmed.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carbon Radioisotopes / therapeutic use. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16971008.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Carbon Radioisotopes
  •  go-up   go-down


30. Singh RP, Agarwal R: Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog; 2006 Jun;45(6):436-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer chemoprevention by silibinin: bench to bedside.
  • Prostate cancer (PCA) is the most invasive malignancy and second leading cause of cancer deaths in American males.
  • PCA progression has also been associated with transition from a paracrine to an autocrine relationship between receptors and growth ligands as this malignancy progresses to an advanced androgen-independent aggressive stage.
  • Silibinin inhibits growth of PCA cells from human, mouse, and rat origins, and also suppresses human prostate tumor xenograft growth in nude mice.
  • Silibinin also inhibits PCA growth in the transgenic adenocarcinoma of mouse prostate (TRAMP) mouse model.
  • Now, silibinin has been entered into phase I/II clinical trials in human PCA patients where preliminary observations were suggestive of its further study in a larger base of the patient population.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16637061.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102514
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / NF-kappa B; 0 / Silymarin; 4RKY41TBTF / silybin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, IGF Type 1
  • [Number-of-references] 20
  •  go-up   go-down


31. Woodle ES, Gupta M, Buell JF, Neff GW, Gross TG, First MR, Hanaway MJ, Trofe J: Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc; 2005 Mar;37(2):958-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience.
  • INTRODUCTION: Prostate adenocarcinoma (PCA) is the second leading cause of cancer-related deaths in men, and with routine prostrate specific antigen (PSA) screening, is being diagnosed with increasing frequency.
  • Tumor recurrence rates in stage I and II disease (14 and 16%) were lower than in stage III disease (36%).
  • PCA recurrence rates are relatively low in patients who initially presented with stage I and II disease, and are half that of patients with stage III disease.
  • [MeSH-major] Adenocarcinoma / complications. Heart Transplantation. Kidney Transplantation. Liver Transplantation. Prostatic Neoplasms / complications


32. Shilo K, Dracheva T, Mani H, Fukuoka J, Sesterhenn IA, Chu WS, Shih JH, Jen J, Travis WD, Franks TJ: Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis. Arch Pathol Lab Med; 2007 Oct;131(10):1555-60
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
  • Among tumor types, 22% of squamous cell carcinoma, 56% of adenocarcinoma, 72% of typical carcinoid, 52% of atypical carcinoid, 70% of large cell neuroendocrine carcinoma, and 51% of small cell lung carcinoma were positive for AMACR.
  • Furthermore, the Kaplan-Meier analysis revealed that the patients with AMACR-positive small cell carcinoma had better survival (19% vs 5% after 5 years, P = .04) than patients with AMACR-negative tumors.
  • Such survival advantage was seen for patients with stage I-II (P = .01) but not stage III-IV small cell carcinomas (P = .58).
  • CONCLUSIONS: These results indicate that, similar to prostate cancer, the overexpression of AMACR frequently occurs in pulmonary carcinomas.
  • Additionally, its positive correlation with outcome of stage I-II small cell lung carcinoma warrants further investigation of the AMACR role in the prognosis of this tumor.
  • [MeSH-major] Adenocarcinoma / enzymology. Biomarkers, Tumor / metabolism. Carcinoma, Neuroendocrine / enzymology. Carcinoma, Squamous Cell / enzymology. Lung Neoplasms / enzymology. Racemases and Epimerases / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922592.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


33. D'Amico AV, Halabi S, Tempany C, Titelbaum D, Philips GK, Loffredo M, McMahon E, Sanford B, Vogelzang NJ, Small EJ, Cancer and Leukemia Group B: Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. Int J Radiat Oncol Biol Phys; 2008 May 1;71(1):9-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study.
  • PATIENTS AND METHODS: Between 1997 and 2001, 180 men with clinical stage T1c-T3cN0M0 adenocarcinoma of the prostate were registered.
  • Multivariable Cox regression analysis was used to assess whether a significant association existed between eMRI-defined TV progression during nAST and time to recurrence adjusting for prostate-specific antigen (PSA) level, Gleason score (8 to 10 or 7 vs. 6 or less) and stage (T3 vs. T1-2).
  • CONCLUSION: Eradicating intraprostatic hormone refractory prostate cancer (HRPC) by maximizing local control and randomized trials assessing whether survival is improved when agents active against HRPC are combined with maximal local therapy are needed in men who progress based on eMRI during nAST.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2004 Jul;64(1):101-5 [15245944.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):5033-41 [17510436.001]
  • [Cites] Radiology. 1994 Jul;192(1):47-54 [8208963.001]
  • [Cites] Urology. 1998 Feb;51(2):287-92 [9495713.001]
  • [Cites] Semin Ultrasound CT MR. 1998 Feb;19(1):67-89 [9503521.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3380-5 [9779716.001]
  • [Cites] JAMA. 2005 Jul 27;294(4):433-9 [16046649.001]
  • [Cites] Radiology. 2006 Feb;238(2):597-603 [16344335.001]
  • [Cites] Nat Clin Pract Urol. 2005 Sep;2(9):434-42 [16474681.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74 [16798415.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3984-90 [16921051.001]
  • [Cites] J Urol. 2006 Dec;176(6 Pt 1):2432-7 [17085122.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1290-5 [17315162.001]
  • [Cites] Int J Cancer. 2004 Mar 1;108(6):877-81 [14712491.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83 [13130113.001]
  • [Cites] J Urol. 2002 Sep;168(3):995-1000 [12187207.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1155 [10561174.001]
  • [Cites] N Engl J Med. 1990 Sep 6;323(10):621-6 [2200965.001]
  • (PMID = 18037582.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA031946-18; United States / NCI NIH HHS / CA / R01 CA111288-01A1; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / CA031946-18; United States / NCI NIH HHS / CA / R01 CA111288; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / U10 CA003927
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS247440; NLM/ PMC2976647
  •  go-up   go-down


34. D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW, Cancer and Leukemia Group B: p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology; 2008 May;71(5):933-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
  • METHODS: Between May 1997 and April 2001, 180 men with clinical stage T1c-T3cN0M0 adenocarcinoma of the prostate were registered on a study evaluating whether the endorectal magnetic resonance imaging (eMRI)-defined change in tumor volume (TV) during neoadjuvant (n) AST was associated with prostate-specific antigen (PSA) outcome.
  • RESULTS: After a median follow-up of 6.9 years and adjusting for PSA level, Gleason score, clinical stage, and eMRI-defined TV change during nAST, men with abnormal compared with normal p53 expression were at increased risk of PSA failure (hazard ratio [HR]: 2.8; 95% confidence interval [CI]: 1.3-5.9; P = 0.008 for the 141; HR: 2.4; 95% CI: 1.1-5.4; P = 0.03 for the 113).
  • CONCLUSIONS: Maximizing local control and randomized trials evaluating the impact on survival of adding novel agents to maximal local therapy are warranted in men whose prostate cancer demonstrates abnormal p53 expression.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / therapy. Flutamide / therapeutic use. Gonadotropin-Releasing Hormone / agonists. Neoplasm Recurrence, Local / epidemiology. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / therapy. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18291508.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA60138; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA77651
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 33515-09-2 / Gonadotropin-Releasing Hormone; 76W6J0943E / Flutamide
  •  go-up   go-down


35. Hashem M, Essam T: Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer. J Egypt Natl Canc Inst; 2005 Jun;17(2):114-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer.
  • BACKGROUND AND AIM: Prostate cancer is a leading cause of death among men worldwide; it is invasive and metastasizes to different organs.
  • The present study is carried out to study the serum levels of hepatocyte growth factor (HGF) in patients with prostate cancer in relation to stage and grade and to evaluate its diagnostic and prognostic clinical validity as a tumor marker.
  • PATIENTS AND METHODS: The study included 47 patients with prostate cancer and 15 apparently healthy men as a control group.
  • The patients were divided into two groups, including 27 patients with localized prostate cancer (group I) and 20 patients with metastatic prostate cancer (group II).
  • Detection of serum levels of HGF and prostate specific antigen (PSA) was carried out by an enzyme immunoassay.
  • RESULTS: The serum levels of HGF and PSA were significantly increased in groups I and II as compared to the control group and were highest in group II.
  • CONCLUSIONS: HGF is elevated in the serum of patients with carcinoma of the prostate and this elevation is related to the stage of malignancy and is independent of age.
  • These results imply that HGF may be an important serum marker for prostate cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / blood. Hepatocyte Growth Factor / blood. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood


36. Pervez N, Small C, MacKenzie M, Yee D, Parliament M, Ghosh S, Mihai A, Amanie J, Murtha A, Field C, Murray D, Fallone G, Pearcey R: Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys; 2010 Jan 1;76(1):57-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
  • PURPOSE: To report acute toxicity resulting from radiotherapy (RT) dose escalation and hypofractionation using intensity-modulated RT (IMRT) treatment combined with androgen suppression in high-risk prostate cancer patients.
  • METHODS AND MATERIALS: Sixty patients with a histological diagnosis of high-risk prostatic adenocarcinoma (having either a clinical Stage of > or =T3a or an initial prostate-specific antigen [PSA] level of > or =20 ng/ml or a Gleason score of 8 to 10 or a combination of a PSA concentration of >15 ng/ml and a Gleason score of 7) were enrolled.
  • RT prescription was 68 Gy in 25 fractions (2.72 Gy/fraction) over 5 weeks to the prostate and proximal seminal vesicles.
  • CONCLUSION: Dose escalation using a hypofractionated schedule to the prostate with concurrent pelvic lymph node RT and long-term androgen suppression therapy is well tolerated acutely.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects
  • [MeSH-minor] Aged. Aged, 80 and over. Androgen Antagonists / therapeutic use. Combined Modality Therapy. Dose Fractionation. Gastrointestinal Tract / radiation effects. Humans. Leuprolide / therapeutic use. Lymphatic Irradiation / adverse effects. Lymphatic Irradiation / methods. Male. Middle Aged. Pelvis. Prospective Studies. Prostate / radiation effects. Prostate-Specific Antigen / blood. Radiation Injuries / pathology. Rectum / radiation effects. Seminal Vesicles / radiation effects. Urinary Bladder / radiation effects. Urogenital System / radiation effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19395192.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; EC 3.4.21.77 / Prostate-Specific Antigen; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


37. Johnke RM, Edwards JM, Evans MJ, Nangami GN, Bakken NT, Kilburn JM, Lee TK, Allison RR, Karlsson UL, Arastu HH: Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression. In Vivo; 2009 Sep-Oct;23(5):827-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression.
  • BACKGROUND: The purpose of this study was to investigate the immunological impact of combining neoadjuvant total androgen suppression (TAS) with radiotherapy (xRT) in the treatment of prostate cancer by monitoring blood cytokine levels.
  • PATIENTS AND METHODS: Participants were stage I-II prostate cancer patients receiving xRT alone (n=18) or TAS+xRT (n=19) under the procedures outlined in RTOG protocols #94-08 and #94-13.
  • [MeSH-major] Adenocarcinoma / blood. Androgen Antagonists / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Cytokines / blood. Prostatic Neoplasms / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779119.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Cytokines
  •  go-up   go-down


38. Camoriano M, Kinney SR, Moser MT, Foster BA, Mohler JL, Trump DL, Karpf AR, Smiraglia DJ: Phenotype-specific CpG island methylation events in a murine model of prostate cancer. Cancer Res; 2008 Jun 1;68(11):4173-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotype-specific CpG island methylation events in a murine model of prostate cancer.
  • Study of advanced prostate cancer phenotypes in the human disease is hampered by limited availability of tissues.
  • We therefore took advantage of the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) model to study whether three different phenotypes of TRAMP tumors (PRIM, late-stage primary tumors; AIP, androgen-independent primary tumors; and MET, metastases) displayed specific patterns of CpG island hypermethylation using Restriction Landmark Genomic Scanning.
  • The CpG island in the human orthologue of BC058385 was methylated in human AIP but not in primary androgen-stimulated prostate cancer or benign prostate.
  • In conclusion, phenotype-specific hypermethylation events were associated with the overexpression of different genes and may provide new markers of prostate tumorigenesis.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6410-4 [8341647.001]
  • [Cites] BMC Genomics. 2007;8:446 [18053125.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):946-51 [7547246.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Urology. 1999 Dec;54(6):1112-9 [10604719.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):179-85 [10861471.001]
  • [Cites] Nature. 2001 Jan 11;409(6817):141, 143-4 [11196623.001]
  • [Cites] J Med Genet. 2001 May;38(5):285-303 [11333864.001]
  • [Cites] Hum Mol Genet. 2001 Jun 15;10(13):1413-9 [11440994.001]
  • [Cites] J Natl Cancer Inst. 2001 Oct 3;93(19):1465-72 [11584062.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 21;93(22):1747-52 [11717336.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S141-4 [11762342.001]
  • [Cites] Genomics. 2002 Jun;79(6):849-59 [12036300.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5414-26 [12154404.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):453-8 [12355068.001]
  • [Cites] Lancet Oncol. 2002 Dec;3(12):755-63 [12473517.001]
  • [Cites] J Med Genet. 2003 Jan;40(1):25-33 [12525538.001]
  • [Cites] J Urol. 2003 Mar;169(3):1138-42 [12576869.001]
  • [Cites] Hum Mol Genet. 2003 Apr 1;12(7):791-801 [12651874.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:110-9 [12724216.001]
  • [Cites] N Engl J Med. 2003 Jul 24;349(4):366-81 [12878745.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):250-9 [14712230.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):440-8 [14760063.001]
  • [Cites] Genomics. 2004 Oct;84(4):647-60 [15475242.001]
  • [Cites] Cancer. 1973 Nov;32(5):1126-30 [4585929.001]
  • [Cites] Nucleic Acids Res. 1983 May 25;11(10):3087-95 [6856456.001]
  • [Cites] Science. 1992 Jul 3;257(5066):50-6 [1621094.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 1;25(21):4422-6 [9336479.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4687-91 [9354422.001]
  • [Cites] Genomics. 1999 Jun 15;58(3):254-62 [10373323.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15785-90 [16243968.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):982-7 [16415157.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):18969-74 [17142318.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11659-67 [17178860.001]
  • [Cites] Biotechniques. 2007 Jan;42(1):48, 50, 52 passim [17269485.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(1):6-14 [17075603.001]
  • [Cites] Nucleic Acids Res. 2007;35(18):e119 [17855397.001]
  • [Cites] Epigenetics. 2007 Sep;2(3):161-72 [17965620.001]
  • [Cites] Clin Invest Med. 1993 Dec;16(6):475-92 [8013153.001]
  • (PMID = 18519676.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA128062-01; United States / NCI NIH HHS / CA / R21 CA121216; United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / CA 16056; United States / NCI NIH HHS / CA / R21 CA128062; United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA077739-070006; United States / NCI NIH HHS / CA / CA128062-01; United States / NCI NIH HHS / CA / P01 CA077739-070006; United States / NCI NIH HHS / CA / P01-NCI-CA77739; United States / NCI NIH HHS / CA / 5T32CA009072; United States / NCI NIH HHS / CA / T32 CA009072
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / neurexin II
  • [Other-IDs] NLM/ NIHMS102969; NLM/ PMC2851167
  •  go-up   go-down


39. Ather MH, Abbas F, Faruqui N, Israr M, Pervez S: Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol; 2008;8:21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
  • BACKGROUND: The importance of immuno-histological detection of neuroendocrine differentiation in prostatic adenocarcinoma with respect to disease at presentation and Gleason grade is gaining acceptance.
  • In the current work we have assessed the correlation of immuno-histological detection of neuroendocrine differentiation in prostatic adenocarcinoma with respect to disease at presentation and Gleason grade and to determine the relative value of various markers.
  • MATERIALS AND METHODS: Consecutive samples of malignant prostatic specimens (Transurethral resection of prostate or radical retropubic prostatectomy) from 84 patients between January 1991 and December 1998 were evaluated by immunohistochemical staining (PAP technique) using selected neuroendocrine tumor markers i.e.
  • According to the stage at diagnosis, patients were divided into three groups.
  • Group (i) included patients who had organ confined disease, group (ii) included patients with locally invasive disease, and group (iii) with distant metastasis.
  • NE expression was correlated with Gleason sum and clinical stage at presentation and analyzed using Chi-Square test and one way ANNOVA.
  • Group I had 14 patients, group II had 31 patients and group III had 39 patients.
  • Expression of CgA was seen in 7% of group I, 37% in group II and 35% of group III patients (p 0.059).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2002 Mar;440(3):241-8 [11889593.001]
  • [Cites] Eur Urol. 2003 Sep;44(3):309-14; discussion 314 [12932928.001]
  • [Cites] Semin Diagn Pathol. 2000 May;17(2):149-61 [10839615.001]
  • [Cites] Int J Urol. 2008 May;15(5):423-8 [18452460.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Urology. 2005 Aug;66(2):386-91 [16098367.001]
  • [Cites] BMC Urol. 2004 Dec 10;4(1):14 [15588310.001]
  • [Cites] Prostate Suppl. 1998;8:37-42 [9690662.001]
  • [Cites] Eur Urol. 1996;30(2):133-7 [8875193.001]
  • [Cites] Cancer. 1992 Jul 1;70(1 Suppl):254-68 [1350941.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):512-5 [11792908.001]
  • [Cites] Endocr Pathol. 2003 Winter;14(4):293-301 [14739487.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3943-53 [15217924.001]
  • [Cites] Adv Anat Pathol. 2004 Jul;11(4):175-89 [15220821.001]
  • [Cites] Prog Clin Biol Res. 1987;243A:529-31 [2889216.001]
  • [Cites] Br J Urol. 1991 Sep;68(3):258-62 [1913066.001]
  • [Cites] Int J Cancer. 1995 Jul 28;62(3):252-8 [7543077.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1240-6 [7977947.001]
  • (PMID = 19115997.001).
  • [ISSN] 1471-2490
  • [Journal-full-title] BMC urology
  • [ISO-abbreviation] BMC Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Other-IDs] NLM/ PMC2628675
  •  go-up   go-down


40. Russell MR, Jamieson WL, Dolloff NG, Fatatis A: The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene; 2009 Jan 22;28(3):412-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
  • Bone resorption by osteoclasts is thought to promote the proliferation of prostate cancer cells disseminated to the skeleton (Mundy, 2002).
  • Using a mouse model of experimental metastasis, we found that although late-stage metastatic tumors were indeed surrounded by osteoclasts, these cells were spatially unrelated to the small foci of cancer cells in early-stage metastases.
  • This is the first evidence that survival and growth of disseminated prostate cancer cells immediately after their extravasation may not depend on osteoclast involvement.
  • Interestingly, prostate cancer cells expressing the alpha-receptor for platelet-derived growth factor (PDGFRalpha) progress during early-stages of skeletal dissemination, whereas cells expressing lower levels or lacking this receptor fail to survive after extravasation in the bone marrow.
  • Finally, functional blockade of human PDGFRalpha on prostate cancer cells utilizing a novel humanized monoclonal antibody -- soon to undergo phase-II clinical trials -- significantly impairs the establishment of early skeletal metastases.
  • In conclusion, our results strongly implicate PDGFRalpha in prostate cancer bone tropism through its promotion of survival and progression of early-metastatic foci, providing ground for therapeutic strategies aimed at preventing or containing the initial progression of skeletal metastases in patients affected by prostate adenocarcinoma.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18850002.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM067892
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


41. Prada PJ, Hevia M, Juan G, Abascal JM, de la Rúa A, Abascal R, Fernández J, Rodríguez R: [I125 low dose rate brachytherapy in localized prostate cancer. Preliminary results after 5 years]. Arch Esp Urol; 2005 Apr;58(3):213-26; discussion 224
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [I125 low dose rate brachytherapy in localized prostate cancer. Preliminary results after 5 years].
  • [Transliterated title] Braquiterapia de baja tasa (I125) en el cáncer de próstata localizado. Resultados preliminares a 5 años.
  • OBJECTIVES: Prostatic brachytherapy by permanent implant of I125 or Pd103 is a therapeutic option in the treatment of organ confined prostate cancer We analyze preliminary results and complications after five years in the group of patients who received I125 low dose rate brachytherapy as the only intention-to-cure treatment and evaluate the differences with the standard treatment (surgery).
  • METHODS: From a case series of more than 400 patients treated with brachytherapy as radical intention-to-cure monotherapy for organ-confined prostate cancer we excluded patients with less than 12 months of follow-up for statistical analysis; the study group includes 275 patients enrolled between april 1999 and December 2003.
  • 93% of the patients presented a clinical stage < or ='3dT2a and 7% T2b, with 60 8% of the cases having a PSA < or ='3d 10 ng/ml.
  • 9% of the cases had a prostate volume > 50 cc.
  • Figure 3 and tables II-VI summarize the complications in various series including this.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Iodine Radioisotopes / administration & dosage. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906615.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Number-of-references] 76
  •  go-up   go-down


42. Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A: Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. Expert Opin Investig Drugs; 2006 Jul;15(7):795-804
Hazardous Substances Data Bank. LEUPROLIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
  • The development of resistance to anticancer therapies is a major hurdle in preventing long-lasting clinical responses to conventional therapies in hormone-refractory prostate cancer.
  • Herein, the molecular evidence documenting that bone metastasis microenvironment survival factors (mainly the paracrine growth hormone-independent, urokinase-type plasminogen activator-mediated increase of IGF-1 and the endocrine production of growth hormone-dependent IGF-1, mainly liver-derived IGF-1 production) produce an epigenetic form of prostate cancer cells that are resistant to proapoptotic therapies is reviewed.
  • Consequently, the authors present the conceptual framework of a novel antibone microenvironment survival factor, mainly an anti-IGF-1 hormonal manipulation for androgen ablation refractory prostate cancer (a combination of conventional androgen ablation therapy [luteinising hormone-releasing hormone agonist-A or orchiectomy]) with dexamethasone plus somatostatin analogue, which yielded durable objective responses and major improvement of bone pain and performance status in stage D3 prostate cancer patients.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Androgen Antagonists / therapeutic use. Androgens / metabolism. Apoptosis. Clinical Trials, Phase II as Topic. Combined Modality Therapy. Dexamethasone / administration & dosage. Dexamethasone / pharmacology. Drug Resistance, Neoplasm. Estramustine / administration & dosage. Etoposide / administration & dosage. Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropin-Releasing Hormone / therapeutic use. Growth Substances / metabolism. Humans. Leuprolide / administration & dosage. Male. Neoplasm Proteins / metabolism. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / metabolism. Neoplasms, Hormone-Dependent / secondary. Neoplasms, Hormone-Dependent / surgery. Orchiectomy. Osteoblasts / metabolism. Osteoclasts / metabolism. Paracrine Communication. Peptides, Cyclic / administration & dosage. Prospective Studies. Randomized Controlled Trials as Topic. Receptors, Androgen / drug effects. Receptors, Androgen / metabolism. Salvage Therapy. Somatostatin / administration & dosage. Somatostatin / analogs & derivatives. Survival Analysis. Triptorelin Pamoate / administration & dosage

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16787142.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Androgens; 0 / Antineoplastic Agents, Hormonal; 0 / Growth Substances; 0 / Neoplasm Proteins; 0 / Peptides, Cyclic; 0 / Receptors, Androgen; 118992-92-0 / lanreotide; 33515-09-2 / Gonadotropin-Releasing Hormone; 35LT29625A / Estramustine; 51110-01-1 / Somatostatin; 57773-63-4 / Triptorelin Pamoate; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; EFY6W0M8TG / Leuprolide
  • [Number-of-references] 79
  •  go-up   go-down


43. Chen C, Chen LQ, Chen LD, Yang GL, Li Y: Evaluation of tumor markers biochip C12 system in the diagnosis of gastric cancer and the strategies for improvement: analysis of 100 cases. Hepatogastroenterology; 2008 May-Jun;55(84):991-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODOLOGY: Sera from 100 gastric carcinoma patients were screened for 12 tumor markers including carcinoembryonic antigen, alpha-fetoprotein, carbohydrate antigen 19-9, carbohydrate antigen 242, cancer antigen 15-3, cancer antigen 125, prostate specific antigen, free-PSA, neuron-specific enolase, human chorionic gonagotropin-beta, human growth hormone, and ferritin, using the C12 biochip system.
  • RESULTS: The overall diagnostic rate of C12 biochip system was 37%, and 7.8%, 29.4%, 35.5% and 50%, respectively, for stages I, II, III and IV patients.
  • The differences in diagnostic rates between stage I (7.8%) and stage IV (50%) reached statistical significance (chi-square test, Chi2=7.20, p<0.01).
  • CONCLUSIONS: The C12 biochip system has some value in the diagnosis of advanced stage gastric cancer, but less sensitive in early gastric cancer.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Carcinoma / diagnosis. Carcinoma / pathology. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / pathology. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705314.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


44. Chen C, Chen LQ, Yang GL, Li Y: Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases. Ai Zheng; 2007 Nov;26(11):1221-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twelve tumor markers were detected in the sera of 130 pathologically confirmed CRC patients, including carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 242 (CA242), cancer antigen 15-3 (CA15-3), cancer antigen 125 (CA125), prostate specific antigen (PSA), free-PSA(f-PSA), neuron-specific enolase (NSE), human chorionic gonagotropin-beta (beta-HCG), human growth hormone (HGH), and ferritin, using the C12 diagnostic biochip system.
  • RESULTS: The overall diagnostic rate for the 130 patients was 42.3%; and the diagnostic rates were 13.6%, 39.5%, 38.2% and 68.8%, for stages I, II, III and IV patients, respectively.
  • There was significant difference in the diagnostic rates between stage I and stage IV patients.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Colorectal Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Antigens, Tumor-Associated, Carbohydrate / blood. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prostate-Specific Antigen / blood. Protein Array Analysis. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991322.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA 242 antigen; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


45. Espinosa M, Cantú D, Herrera N, Lopez CM, De la Garza JG, Maldonado V, Melendez-Zajgla J: Inhibitors of apoptosis proteins in human cervical cancer. BMC Cancer; 2006;6:45
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study included 8 stage I cases; 16 stage II; 17 stageIII; and a control group of 6 samples of normal cervical squamous epithelial tissue.
  • We found no association between survivin expression and age, clinical stage, histology or menopausal state.
  • Nevertheless, we found that adenocarcinoma tumors expressed higher levels of survivin 2B and DeltaEx3 (p = 0.001 and p = 0.04 respectively, by Kruskal-Wallis).
  • A multivariate Cox's partial likelihood-based analysis showed that only FIGO stage was an independent predictor of outcome.
  • We have found that adenocarcinoma presented higher levels of survivin isoforms 2B and DeltaEx3.
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Cell Line, Tumor. Female. Humans. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2001 May;21(10):3604-8 [11313486.001]
  • [Cites] Oncogene. 2000 Feb 24;19(9):1123-31 [10713699.001]
  • [Cites] Eur J Cancer. 2001 Jun;37(9):1104-10 [11378340.001]
  • [Cites] Apoptosis. 2001 Aug;6(4):253-61 [11445667.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2613-22 [11965534.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2A):805-8 [12014654.001]
  • [Cites] Nat Rev Immunol. 2002 Sep;2(9):664-74 [12209135.001]
  • [Cites] Cell Mol Life Sci. 2002 Aug;59(8):1406-12 [12363043.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):559-63 [12461612.001]
  • [Cites] Oncol Rep. 2003 Jan-Feb;10(1):45-9 [12469143.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):280-8 [12482981.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1077-83 [12671708.001]
  • [Cites] J Neurosurg. 2003 Oct;99(4):738-45 [14567610.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6815-24 [14583479.001]
  • [Cites] Prostate. 2004 Jun 1;59(4):419-25 [15065090.001]
  • [Cites] Semin Cancer Biol. 2004 Aug;14(4):231-43 [15219616.001]
  • [Cites] Mol Ther. 2004 Jul;10(1):162-71 [15233951.001]
  • [Cites] Oncogene. 2004 Sep 16;23(42):7047-52 [15258565.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7183-90 [15492230.001]
  • [Cites] Epidemiol Rev. 1993;15(2):486-98 [8174668.001]
  • [Cites] Cell. 1995 Dec 29;83(7):1243-52 [8548810.001]
  • [Cites] Nature. 1997 Jul 17;388(6639):300-4 [9230442.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5071-4 [9823313.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] Genes Dev. 1999 Feb 1;13(3):239-52 [9990849.001]
  • [Cites] Cancer Lett. 2004 Dec 28;216(2):147-55 [15533590.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):210-8 [15665297.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jan-Feb;15(1):113-9 [15670305.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):120-4 [15611790.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1474-82 [15746049.001]
  • [Cites] Cancer Cell. 2005 May;7(5):457-68 [15894266.001]
  • [Cites] Oncogene. 2000 Mar 2;19(10):1346-53 [10713676.001]
  • [Cites] Lab Invest. 1999 Nov;79(11):1327-33 [10576203.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6097-102 [10626797.001]
  • [Cites] Biochem Pharmacol. 2001 Jul 1;62(1):13-9 [11377392.001]
  • (PMID = 16504151.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human
  • [Other-IDs] NLM/ PMC1403791
  •  go-up   go-down


46. Matsuo T, Nakamura K, Takamoto N, Kodama J, Hongo A, Abrzua F, Nasu Y, Kumon H, Hiramatsu Y: Expression of the serine protease hepsin and clinical outcome of human endometrial cancer. Anticancer Res; 2008 Jan-Feb;28(1A):159-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hepsin is a type II transmembrane serine protease originally identified in the human liver as a cDNA clone.
  • Hepsin was found to be significantly overexpressed in cancer samples compared to matched various tissues (e.g. prostate, renal, ovarian carcinoma).
  • PATIENTS AND METHODS: Hepsin expression was examined by immunohistochemisty in 34 cases with normal endometrium as a control, 11 cases with endometrial hyperplasia, and 128 cases with endometrioid adenocarcinoma.
  • High levels of hepsin expression were associated with advanced stage (p<0.001), high grade (p=0.002), depth of myometrial invasion (p<0.001), cervical involvement (p=0.007), lymph node metastasis (p=0.001), lymph vascular space (LVS) involvement (p=0.006), ovarian metastasis (p=0.002), and peritoneal cytology (p=0.03) of endometrial cancer.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383840.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / hepsin
  •  go-up   go-down


47. Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Church T, Yurgalevitch S, Austin JH, Prorok PC, Gohagan JK, PLCO Project Team: Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst; 2005 Jul 6;97(13):989-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening, including the effect of flexible sigmoidoscopy screening on colorectal cancer mortality.
  • Approximately 77% (130/169) of the colorectal adenocarcinoma patients were stage I or II at diagnosis.
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / mortality. Age Distribution. Aged. Carcinoma / diagnosis. Carcinoma / mortality. Colonic Polyps / diagnosis. Colonic Polyps / mortality. Female. Humans. Male. Middle Aged. Sex Distribution. Surveys and Questionnaires. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15998952.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


48. Blum KA, Johnson JL, Niedzwiecki D, Piro LD, Saven A, Peterson BA, Byrd JC, Cheson BD, Cancer and Leukemia Group B Study 9153: Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Cancer; 2006 Dec 15;107(12):2817-25
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: For this multicenter, single-arm, Phase II study, 44 patients with treatment-naive, stage III or IV, indolent NHL (International Working Formulation subtypes A, B, and C) were enrolled.
  • Four late malignancies (prostate adenocarcinoma, ductal carcinoma in situ, and myelodysplasia) and 4 patients with large cell transformation were reported.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 17120198.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA04457; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA26806; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA47555; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / CA77658
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down


49. Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IeM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB: IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol; 2009 Mar;22(3):469-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype.
  • Clear cell carcinoma is an uncommon subtype of ovarian carcinoma, accounting for 10% of cases.
  • Clear cell carcinoma typically presents with stage I or II disease, and in this setting prognostic markers could aid in management decisions, in particular the decision to treat with adjuvant chemotherapy.
  • We tested whether expression of insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3, also known as IMP3) can serve as a new biomarker to predict outcome for patients with clear cell carcinoma and other subtypes of ovarian carcinoma.
  • We conclude that IGF2BP3 is the first biomarker of prognostic significance in ovarian clear cell carcinoma that has been validated in an independent case series.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / analysis. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / metabolism. RNA-Binding Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136932.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


50. Shanmugam C, Jhala NC, Katkoori VR, Wan W, Meleth S, Grizzle WE, Manne U: Prognostic value of mucin 4 expression in colorectal adenocarcinomas. Cancer; 2010 Aug 01;116(15):3577-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients who had early stage tumors (stages I and II) with high MUC4 expression had a shorter disease-specific survival (log-rank; P=.007) than patients who had with low expression.
  • Patients who had advanced-stage CRCs (stages III and IV) did not demonstrate such a difference (log-rank; P=.108).
  • Multivariate regression models that were generated separately for patients with early stage and advanced-stage CRC confirmed that increased expression of MUC4 was an independent indicator of a poor prognosis only for patients who had early stage CRCs (hazard ratio, 3.77; 95% confidence interval, 1.46-9.73).
  • CONCLUSIONS: The current results indicated that increased MUC4 expression is a predictor of poor survival in CRC, specifically for patients who have early stage tumors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • [Cites] Gastroenterology. 1994 Apr;106(4):1054-61 [8143972.001]
  • [Cites] Cancer Res. 1992 Nov 1;52(21):5971-8 [1394223.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1054-9 [8683636.001]
  • [Cites] J Clin Pathol. 1996 Jul;49(7):560-4 [8813954.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):346-58 [9221816.001]
  • [Cites] J Histochem Cytochem. 1999 Aug;47(8):1063-74 [10424891.001]
  • [Cites] Cancer. 2005 May 15;103(10):2163-70 [15816050.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):806-13 [15897748.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):881-9 [15958852.001]
  • [Cites] J Clin Pathol. 2005 Aug;58(8):845-52 [16049287.001]
  • [Cites] Prostate. 2006 Mar 1;66(4):421-9 [16302265.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64 [16857800.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1386-94 [16880776.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • [Cites] Lung Cancer. 2007 Feb;55(2):195-203 [17126950.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Arch Pathol Lab Med. 2007 Apr;131(4):593-8 [17425390.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):309-20 [17406026.001]
  • [Cites] Eur J Clin Invest. 2007 May;37(5):416-24 [17461988.001]
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):345-57 [17595659.001]
  • [Cites] J Histochem Cytochem. 2008 Mar;56(3):305-12 [18071066.001]
  • [Cites] FASEB J. 2008 Apr;22(4):966-81 [18024835.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2065-70 [18381409.001]
  • [Cites] Eur J Cancer. 2008 May;44(7):1048-56 [18397823.001]
  • [Cites] FASEB J. 2008 Aug;22(8):3035-45 [18492726.001]
  • [Cites] Oncol Rep. 2009 Jan;21(1):49-56 [19082442.001]
  • [Cites] Br J Cancer. 2009 Jan 27;100(2):344-51 [19127263.001]
  • [Cites] Dig Dis. 1999;17(2):67-79 [10545712.001]
  • [Cites] Histopathology. 2000 Feb;36(2):121-6 [10672056.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4017-25 [11051251.001]
  • [Cites] Oncogene. 2001 Jan 25;20(4):461-70 [11313977.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4033-40 [11751498.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] J Histochem Cytochem. 2004 Feb;52(2):253-61 [14729877.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):150-7 [14657954.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] Head Neck. 2004 Apr;26(4):353-64 [15054739.001]
  • [Cites] Laryngoscope. 2004 Aug;114(8 Pt 2 Suppl 101):1-32 [15284539.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1633-8 [15494719.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):953-64 [7657125.001]
  • (PMID = 20564074.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U54 CA118623; United States / NCI NIH HHS / CA / U54 CA118948; United States / NCI NIH HHS / CA / 2U54-CA118948-03; United States / NCI NIH HHS / CA / R01 CA098932; United States / NCI NIH HHS / CA / U24-CA086359; United States / NCI NIH HHS / CA / R01-CA98932-01; United States / NCI NIH HHS / CA / R03-CA139629-01; United States / NCI NIH HHS / CA / R03 CA139629; United States / NCI NIH HHS / CA / R03 CA139629-01; United States / NCI NIH HHS / CA / U24 CA086359
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucin-4
  • [Other-IDs] NLM/ NIHMS189749; NLM/ PMC2910814
  •  go-up   go-down


51. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K: Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer; 2006;5:62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The involvement of the cyclooxygenases (COX), in particular COX-2, is well documented for many tumours, e.g. colon, breast and prostate cancer, by both experimental and clinical studies.
  • The increase of COX-2 was also correlated to stage (FIGO classification) with significant elevations in stages II and III.
  • EP1 was increased in stage III while no significant alterations were demonstrated for COX-1, mPGES-1 or EP2 for stage.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / metabolism. Densitometry. Disease Progression. Epithelial Cells / pathology. Female. Humans. Immunoblotting. Immunohistochemistry. Intramolecular Oxidoreductases / metabolism. Neoplasm Staging. Ovary / metabolism. Receptors, Prostaglandin E / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Soc Gynecol Investig. 2002 May-Jun;9(3):168-73 [12009392.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2002;21(2):149-53 [12086401.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1205-11 [12181243.001]
  • [Cites] J Reprod Immunol. 2002 Oct-Nov;57(1-2):47-60 [12385833.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1423-9 [14508829.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1298-304 [14520463.001]
  • [Cites] Prog Lipid Res. 2004 Jan;43(1):3-35 [14636669.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8653-61 [14647459.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2607-23 [14669280.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):309-13 [14719060.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):538-45 [14760075.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):622-7 [14766256.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4670-9 [15269139.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Sep;83(9):783-95 [15315588.001]
  • [Cites] Reproduction. 2004 Nov;128(5):607-14 [15509706.001]
  • [Cites] Lancet. 1971 Jul 17;2(7716):163 [4104488.001]
  • [Cites] Gynecol Oncol. 1983 Dec;16(3):340-5 [6360817.001]
  • [Cites] Gynecol Obstet Invest. 1984;18(5):225-9 [6396175.001]
  • [Cites] Prostaglandins. 1985 May;29(5):665-72 [3859890.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):275-80 [9221804.001]
  • [Cites] J Histochem Cytochem. 1998 Jan;46(1):77-84 [9405496.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1240-8 [10098766.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10501-6 [10468638.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1927-33 [15870720.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Aug;73(2):103-11 [15963707.001]
  • [Cites] Oncogene. 2005 Dec 1;24(54):7991-8002 [16044148.001]
  • [Cites] Nucleic Acids Res. 2006;34(1):217-31 [16397300.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1884-91 [16287068.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2527-31 [16510568.001]
  • [Cites] Curr Pharm Des. 2006;12(8):943-54 [16533161.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Obstet Gynecol. 2005 Mar;192(3):819-25 [15746677.001]
  • [Cites] Oncol Rep. 2005 Apr;13(4):559-83 [15756426.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3735-44 [15867369.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3250-6 [15867220.001]
  • [Cites] J Reprod Fertil. 2000 Mar;118(2):375-85 [10864803.001]
  • [Cites] Epidemiology. 2000 Mar;11(2):111-7 [11021606.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:661-90 [11264472.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2328-34 [11280806.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Int J Mol Med. 2001 Jul;8(1):31-6 [11408945.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2496-504 [11489832.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7305-9 [11585770.001]
  • [Cites] Int J Mol Med. 2001 Dec;8(6):603-6 [11712072.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):202-9 [11801560.001]
  • [Cites] Annu Rev Physiol. 2002;64:69-92 [11826264.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):893-903 [11891188.001]
  • (PMID = 17107625.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Prostaglandin E; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / prostaglandin-E synthase; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC1657027
  •  go-up   go-down


52. Liang JT, Lai HS, Lee PH, Chang KJ: Laparoscopic pelvic autonomic nerve-preserving surgery for sigmoid colon cancer. Ann Surg Oncol; 2008 Jun;15(6):1609-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The genitourinary function was evaluated on the basis of validated questionnaires including International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF), and Female Sexual Function Index (FSFI).
  • RESULTS: A total of 112 patients (tumor, node, metastasis system stage I, n = 8; stage II, n = 54; stage III, n = 50; male, n = 58; female, n = 54; age [mean +/- standard deviation], 55.8 +/- 6.4 years) with good baseline genitourinary function were operated on with the intent of total preservation of pelvic autonomic nerves and curative resection of sigmoid colon cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Autonomic Pathways / surgery. Colectomy. Sigmoid Neoplasms / surgery. Trauma, Nervous System / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2004 Apr;91(4):465-8 [15048749.001]
  • [Cites] Tech Coloproctol. 2003 Apr;7(1):29-33 [12750952.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2354-61 [16408331.001]
  • [Cites] Br J Surg. 2005 Nov;92(11):1444-8 [16184622.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1124-32 [15997446.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):212-23 [16041212.001]
  • [Cites] World J Surg. 2003 Feb;27(2):190-6 [12616435.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1178-85 [12352233.001]
  • [Cites] J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208 [10782451.001]
  • [Cites] Semin Surg Oncol. 2000 Apr-May;18(3):235-43 [10757889.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1354-7 [15362751.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2206-14 [9951896.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1285-7 [17235719.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):109-17 [17066227.001]
  • [Cites] Int J Clin Oncol. 2006 Oct;11(5):339-43 [17058130.001]
  • [Cites] Dis Colon Rectum. 2004 Sep;47(9):1442-7 [15486739.001]
  • [Cites] Ann Surg. 1988 Oct;208(4):391-400 [3178328.001]
  • [Cites] Dis Colon Rectum. 1995 Nov;38(11):1162-8 [7587758.001]
  • [Cites] Cancer. 1996 Nov 1;78(9):1871-80 [8909305.001]
  • [Cites] Br J Surg. 1997 Apr;84(4):586-7 [9112939.001]
  • [Cites] Urology. 1997 Jun;49(6):822-30 [9187685.001]
  • [Cites] Br J Surg. 1998 Aug;85(8):1162 [9718031.001]
  • (PMID = 18365285.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2373867
  •  go-up   go-down






Advertisement